SLC5A2 and type 2 diabetes mellitus: The present study could provide new insight into the effects of SGLT2 inhibitors on hepatic steatosis, and SGLT2 inhibitors can be potentially considered as an optional treatment of T2DM patients with hepatic steatosis.